menu
    • menu
    [{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha-4 integrin","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"KDT-3594","moa":"Dopamine receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Affamed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Affamed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Rovatirelin","moa":"TRHR","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kissei Pharmaceutical \/ CG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ CG Oncology"}]

    Find Clinical Drug Pipeline Developments & Deals by Kissei Pharmaceutical

    Menu

    Kissei Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Tai Tien Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma Signs Fostamatinib Sub-Licensing Agreement with Kissei

                            Details : Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.

                            Product Name : Tavalisse

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Tai Tien Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cretostimogene Grenadenorepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CG Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Participation in Global Phase III Clinical Trial For CG0070, a Drug for Bladder Cancer

                            Details : CG0070, a oncolytic immunotherapy in which adenovirus is genetically modified to enhance bladder tumor cells selectivity and anticancer activity, and is injected into the bladder using a urinary tract catheter.

                            Product Name : CG0070

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 24, 2021

                            Lead Product(s) : Cretostimogene Grenadenorepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CG Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotegrast Methyl

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : EA Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Results of Phase III Clinical Study of AJM300 for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/C...

                            Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.

                            Product Name : AJM300

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 13, 2021

                            Lead Product(s) : Carotegrast Methyl

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : EA Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KDT-3594

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Affamed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease

                            Details : Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines.

                            Product Name : KDT-3594

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 10, 2020

                            Lead Product(s) : KDT-3594

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Affamed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rovatirelin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment ...

                            Details : In this paper, to review the results of both phase III clinical trials, a pooled (post hoc) analysis was performed with patients who met the inclusion criteria for the additional phase III trial

                            Product Name : KPS-0373

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 22, 2020

                            Lead Product(s) : Rovatirelin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth